Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

Amygdala Acquires Phase II-Ready Addiction Candidate from Gilead

Amygdala Neurosciences has acquired the mid-stage behavior and substance addictions candidate GS-6637 from Gilead Sciences for an undisclosed price. ...

Forward this item to a colleague:


(Separate multiple addresses by commas)